Abemaciclib
Tracked across 1 events · 6 articles · First seen Sep 18, 2026 · Last active Sep 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Eli Lilly and Company announced that the U.S. United States — Food and Drug Administration granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in combination with Abemaciclib (abemaciclib), a CDK4/6 inhibitor, for…
Impact: Abemaciclib gains an additional approved combination use, broadening its label and potential patient population in ESR1-mutated breast cancer.
Sep 18, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Abemaciclib live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard